Sequential Treatment Initiation with Japanese Cedar droplet and HDM tablet Sublingual Immunotherapy Followed by Simultaneous Treatment
Phase 1
- Conditions
- Allergic Rhinitis
- Registration Number
- JPRN-UMIN000024129
- Lead Sponsor
- niversity of Yamanashi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Received Japanese cedar pollen or house dust mite aleergen immunotherapy (2)Taking any immunosuppressive drugs or any anticancer drugs (3)Patients with upper respiratory inflammation, respiratory infection, or severe bronchial asthma (4)Patients with severe cardiac, hepatic, kidney disease (5)Pregnant women and those at risk of pregnancy, lactating woman (6)Recruited anothere clinical trial within 6 month (7)Patients who the doctor judged inaproppriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of adverse events in CTCAE v4.0 and Grading system for SLIT local AEs
- Secondary Outcome Measures
Name Time Method Symptom score,VAS, QOL Questionaire score(RQLQ,JRQLQ), Change of Biomarkers in blood